Published June 10, 2026 | Version v1

MODERN TREATMENT METHODS OF HEART FAILURE

  • 1. Central Asian Medical University, Assistant of the Department of Physiology and Pharmacology

Description

Heart failure is one of the leading causes of morbidity and mortality worldwide and remains a major challenge for modern healthcare systems. The increasing prevalence of cardiovascular diseases, population aging, hypertension, diabetes mellitus, and obesity has contributed to the growing burden of heart failure. Recent advances in cardiovascular medicine have led to the development of innovative treatment strategies that significantly improve patient outcomes. This article examines contemporary approaches to heart failure management, including pharmacological therapy, device-based interventions, and advanced treatment options for severe cases. Particular attention is given to angiotensin receptor-neprilysin inhibitors, beta-blockers, mineralocorticoid receptor antagonists, sodium-glucose cotransporter-2 inhibitors, implantable cardiac devices, mechanical circulatory support systems, and heart transplantation. The article also discusses future perspectives in heart failure treatment, including personalized medicine, artificial intelligence, gene therapy, and regenerative medicine. The findings indicate that modern multidisciplinary approaches contribute to improved survival, reduced hospitalization rates, and enhanced quality of life among patients with heart failure.

Files

265-271 Umurqulov.pdf

Files (394.5 kB)

Name Size
md5:cb9fe7d008be2f1e81c1f33562f715f5
394.5 kB Preview Download

Additional details

References

  • 1. Heidenreich P.A., Bozkurt B., Aguilar D. et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure // Circulation. – 2022. – Vol. 145, No. 18. – P. e895–e1032
  • 2. Anker S.D., Butler J., Filippatos G. et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction // New England Journal of Medicine. – 2021. – Vol. 385, No. 16. – P. 1451–1461.
  • 3. Packer M., Anker S.D., Butler J. et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure // New England Journal of Medicine. – 2020. – Vol. 383, No. 15. – P. 1413–1424.
  • 4. Yancy C.W., Januzzi J.L., Allen L.A. et al. 2021 ACC Expert Consensus Decision Pathway on Heart Failure Treatment Optimization // Journal of the American College of Cardiology. – 2021. – Vol. 79, No. 17. – P. 1757–1780.
  • 5. Beghini A., Rosano G.M.C., Metra M. 2024 Update in Heart Failure // European Journal of Heart Failure. – 2024. – Vol. 26, No. 1. – P. 8–25